Apr 20,2023

Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial

Pretreatment identification of pathological extranodal extension (ENE) would guide therapy de-escalation strategies for in human papillomavirus (HPV)-associated oropharyngeal carcinoma but is diagnostically challenging. Researchers aimed to evaluate a CT-based deep learning algorithm for prediction of ENE in E3311, a diagnostically challenging cohort wherein algorithm use would be impactful in guiding decision-making. For this retrospective evaluation of deep learning algorithm performance, the research obtained pretreatment CTs and corresponding surgical pathology reports from the multicentre, randomised de-escalation trial E3311. Deep learning algorithm performance for ENE prediction was compared with four board-certified head and neck radiologists. The primary endpoint was the area under the curve (AUC) of the receiver operating characteristic. From 178 collected scans, 313 nodes were annotated: 71 (23%) with ENE in general, 39 (13%) with ENE larger than 1 mm ENE. The deep learning algorithm AUC for ENE classification was 0·86 (95% CI 0·82–0·90), outperforming all readers (p<0·0001 for each).

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 20,2023

Real-world data control arm provides new look into effectiveness of lymphoma therapies

Real-world data can uncover vital efficacy info for new treatments. In the development of an external control arm for lisocabtagene maraleucel in patients with R/R large B-cell lymphoma, Bristol Myers Squibb used COTA’s RWD. Using real-world data from COTA and other sources, the team developed an external control arm to provide additional context around the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional (noncellular) therapies in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 19,2023

Partnership Aims to Detect Bladder Tumors Earlier with Help of AI Hackensack Meridian Health Teams Up with Etta.io in New Collaboration

Hackensack Meridian Health, the state’s largest and most comprehensive health network, is partnering with Etta.io., a Denver-based healthcare technology startup that builds Artificial Intelligence (AI) applications to detect tumors difficult to see with the naked eye, even for specialists. The partnership aims to develop an AI based product/solution utilizing the potential of endoscopic images of the bladder to detect early-stage Carcinoma in situ (CIS). The investment and collaboration is being spearheaded by the health network’s Office of Innovation and Commercialization and the Bear’s Den Innovation Program within the Hackensack Meridian Health Research Institute (HMHRI).

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 19,2023

Qure.ai Joins Nuance Precision Imaging Network to Enhance Patient Outcomes with AI-Integrated Workflows for Care Teams

Qure.ai announced that it has connected to the Nuance Precision Imaging Network™. The secure nationwide cloud platform empowers collaborative care teams with streamlined communications and AI insights from diagnostic imaging within existing workflows to improve healthcare outcomes and costs.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 17,2023

New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification

Veracyte, Inc. (Nasdaq: VCYT) announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease (difficult-to-detect tumor cells that extend beyond the prostate) and who may therefore benefit from systemic treatment intensification. The researchers found that there was a significant correlation between patients’ Decipher Prostate scores and the risk of upstaging on PSMA PET, and that high Decipher scores were especially enriched in patients at the highest risk of harboring disease outside their prostate. Accordingly, these patients would be more likely to benefit from systemic treatment intensification as compared to local therapy.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Apr 14,2023

Precision Cancer Consortium announces new industry member and leadership succession as it celebrates its one-year anniversary

The Precision Cancer Consortium (PCC) is pleased to announce the addition of AstraZeneca as its newest member. The PCC now consists of seven member organizations, AstraZeneca, Bayer, Eli Lilly and Company, GSK, Janssen, Novartis, and Roche, who are collaborating to support efforts to improve patient access to comprehensive genomic testing in routine care and in clinical trials globally.

View Analyst & Ambassador Comments
Go to original news
Apr 14,2023

Tempus Announces Seven Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced seven abstracts were accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 14-19, in Orlando, Florida. Tempus researchers will demonstrate how the company’s AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 13,2023

Creating an Artificial Pathologist

A team from the Max Planck Institute for the Science of Light (MPL) in Erlangen has created a new, fast and precise method for clinicians to analyse cells in tissue samples from cancer patients without the need for a trained pathologist. They use artificial intelligence to evaluate the data their method produces. Using a personalised approach to guide treatment could improve life expectancy, quality of life and reduce unnecessary side effects of cancer patients.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 12,2023

Agilent and PathAI Partner to Deliver AI-Powered Assay Development Solutions for Biopharma Research and Clinical Applications

Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for pathology, to deliver biopharmaceutical organizations a solution that combines Agilent’s assay development expertise and PathAI’s algorithm development capabilities. By incorporating AI into CDx development, the partnership enables Agilent and PathAI to build integrated solutions with assays and machine learning analysis algorithms. Through this partnership, biopharmaceutical companies can harness an end-to-end solution for AI-powered assay development, including companion diagnostics enabled by digital pathology. In line with that vision, Agilent also announces a multiyear global distribution agreement with PathAI to distribute both versions of their platform AISight and AISight DX+ along with AIM-PD-L1 NSCLC, an algorithm for PD-L1 quantification in non-small cell lung cancer (NSCLC), to anatomic pathology laboratories. Further, through this partnership, Agilent may also commercialize additional algorithms PathAI launches in the future.

COLLABORATION PARTNERSHIP

#r&d

#cdx

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 12,2023

Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting

Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news